

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2005/003715

International filing date: 04 February 2005 (04.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/542,391

Filing date: 06 February 2004 (06.02.2004)

Date of receipt at the International Bureau: 11 April 2007 (11.04.2007)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1595129

UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 05, 2007

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/542,391

FILING DATE: *February 06, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/03715

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY
APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS
CONVENTION, IS US60/542,391



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

020604
16085 U.S.PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/16 (05-03)
Approved for use through 4/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EV306257983US

22261 U.S.PTO
007542391
020604**INVENTOR(S)**

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
David J.	Kyle	Catonsville, MD

Additional inventors are being named on the 1 separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

RNA-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals

Direct all correspondence to:

CORRESPONDENCE ADDRESS

Customer Number

08933

Place Customer Number
Bar Code Label here

OR

Type Customer Number here

Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

ENCLOSED APPLICATION PARTS (check all that apply)

Specification Number of Pages

43

CD(s), Number

Drawing(s) Number of Sheets

Other (specify)

Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

Applicant claims small entity status. See 37 CFR 1.27.

FILING FEE
AMOUNT (\$)

A check or money order is enclosed to cover the filing fees

The Commissioner is hereby authorized to charge filing
fees or credit any overpayment to Deposit Account Number:

04-1679

\$80.00

Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the
United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME

Gary D. Colby

TELEPHONE

215-979-1849

Date

02/06/2004

REGISTRATION NO.
(if appropriate)
Docket Number:

40,961

PA37

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number	PA37
---------------	------

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Arun	Dhar	San Diego, CA

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

US PROVISIONAL PATENT APPLICATION

OF

ARUN K. DHAR

DAVID J. KYLE

FOR

**RNA-MEDIATED INTERFERENCE TO CONTROL DISEASE IN TERRESTRIAL AND
AQUACULTURE ANIMALS**

BACKGROUND OF THE INVENTION

Disease prevention in agriculture and aquaculture is a major focus to maximize both the health of the animals and the commercial viability of raising these animals. Pharmaceuticals and vaccines have a place in this effort, but a less expensive and less invasive method to cure or prevent the symptoms of specific diseases is needed in order to minimize the discomfort of the animals as well as to maximize profits in their growth.

One example is shrimp aquaculture. Over the past few decades, shrimp (*Penaeus* sp.) farming has evolved from a subsistence level of farming to a major industry providing jobs directly and indirectly to millions of people around the globe. As the shrimp farming evolves, it is poised with many challenges. Among them, viral diseases are of major concern to shrimp farmers. Over the last few years disease like white spot disease, caused by the white spot syndrome virus (WSSV), have caused severe epizootics in the shrimp farming regions of Asia, Central and South America resulting colossal losses (Krishna et al. 1997; Jory and Dixon 1999). WSSV contains a circular double-stranded DNA genome of ~300 kb in length, and infects all commercially important species of penaeid shrimp and a number of other crustaceans including crabs and crayfish (Flegel 1997; van Hulten et al. 2001; Yang et al. 2001). Since the initial record of the WSSV in East Asia during 1992 to 1993 (Inouye et al. 1994), a number of WSSV encoded genes such as the capsid genes (van Hulten et al. 2000a; van Hulten et al. 2000b; Zhang et al. 2001; Chen et al. 2002; Marks et al. 2003); a ribonucleotide reductase gene (Tsai et al. 2000a); and the thymidine kinases (Tsai et al. 2000b) have been studied in detail. In addition, a highly sensitive detection method based on real-time PCR has also been developed for detecting and quantifying the WSSV (Dhar et al. 2001). However, efforts towards developing therapeutics for white spot disease have been very limited. Only recently, it has been reported that addition of β -1,3-glucan as an additive to shrimp diet at a level of 10 g per kg for 20 days enhances the immunity of shrimp and subsequent survivability against WSSV infection (Chang et al. 2003). Using phage display, Yi et al. (Yi et al. 2003) have identified a small 10-mer peptide (2E6) that has a high specificity for WSSV, and blocked WSSV-infection in crayfish. Injection of

recombinant WSSV capsid proteins (VP 26 and VP 28) was shown to induce resistance in shrimp (*P. japonicus*) (Namikoshia et al. 2004).

Shrimp, like other crustaceans, do not have adaptive immunity. Instead they rely on the innate immune response. Although many immune genes involved in bacterial and fungal immunity in invertebrates have been well characterized, very few immune genes involved in viral pathogenesis in shrimp or any other invertebrates are known to date. Therefore, there is an urgent need to isolating and characterizing the immune genes in shrimp and to developing therapeutics to combat viral disease in shrimp.

In recent years, a phenomenon called RNA interference (RNAi) has been used to knocking down the expression of a target gene (both cellular and viral genes as target gene) (Xia et al. 2002; McCown et al. 2003; Wilson et al. 2003), without causing global changes in gene expression in cells. RNAi is a phenomenon in which a double stranded RNA (dsRNA) suppresses the expression of a target gene by enhancing the specific degradation of the complementary target mRNA (Hannon 2002). The mechanism of RNAi involves recognition of the dsRNA by the enzyme RNase III and its cleavage into 21-23 nucleotide short interfering RNA (siRNA). The siRNA is then incorporated into an RNAi targeting complex known as RNA-induced silencing complex (RISC), and cleave the target mRNA that is homologous to siRNA. This results in rapid degradation of the target mRNA and decrease in protein synthesis (Hannon 2002). It has been shown recently that RNA mediated interference can be attained through ingestion of dsRNA in *Caenorhabditis elegans* (Kamath et al., 2002).

The goal of this invention is to use the RNAi phenomenon to develop therapeutics for the control of viral and bacterial diseases in shrimp, aquaculture, and terrestrial species. Double stranded RNA is fed orally to animals through diets and their efficiency in preventing the disease is measured. Methods are developed for controlling the white spot syndrome disease in shrimp. Five WSSV genes are used as target genes including a WSSV encoded early expressed gene (ribonucleotide reductase), a protease inhibitor, a DNA polymerase gene, a nucleocapsid gene (VP26) and a capsid gene (VP28). A 21-23 nucleotide long WSSV DNA representing these genes are chemically synthesized, and cloned into a feeding vector (L4440). The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible

expression of T7 polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying WSSV specific genes are sequenced to confirm the identity. The whole bacterial cell or broken cells is mixed with diet and fed to shrimp. Shrimp is challenged orally with live infectious WSSV and the mortality is scored. The mRNA expression of the five WSSV target genes is also measured in the treated and control animals using real-time RT-PCR (Dhar et al. 2001; Dhar et al. 2003) to determine the difference in expression in two treatment groups.

Significant disease challenges also exist in other aquacultured species as well as terrestrial animals. In cows, sheep, and goats slow growing organisms such as the Mycobacteria cause extensive damage and destruction of herds. Johne's disease (caused by *Mycobacterium paratuberculosis johnii*) is an example of type of disease. Other slow growing bacteria that could be treated with this approach are the Mycoplasmas. Bovine diseases such as *Neospora caninum*, brucellosis, tuberculosis, bovine leucosis, and diarrhea could be controlled using the instant invention. Protozoan diseases of animals caused by protozoans such as *Cryptosporidia* and *Giardia* could be addressed. Viral diseases such as bovine diarrhea and corona virus could also be addressed. A chronic problem in chicken husbandry is the presence of salmonellidae. In addition there are a number of viral diseases that cause extensive damage, such as infectious bronchitis, exotic Newcastle disease, avian influenza (causing the destruction of millions of birds).

Alternative systems exist that could provide cost advantages for any RNAi product produced in these systems *versus* bacterial systems. Such systems could be algal (e.g., *Synechocystis* or *Chlorella*), fungal (e.g., *Aspergillus niger*, *Neurospora crassa*), plant (e.g., tobacco, alfalfa, potato, *Arabidopsis*), and insects (e.g., *T. ni* and *Spodoptera frugiperda*). The molecular tools necessary to produce dsRNA constructs in bacterial systems could easily be adapted to these other organisms and, at least for the purposes of this invention, could provide advantages in production costs of the biomass that would be incorporated into a feed. For the purposes of this invention, focus is placed on the plant system. However, expression tools are well developed in the other systems as evidenced by the following references that are included herein by reference for the tools in fungal systems (1990; el-Enshasy et al. 2001; Wiebe et al.

2001; Liu et al. 2003), algal (Mayfield and Kindle 1990; Moll 1993; Villand et al. 1999; Choi et al. 2000; Toyomizu et al. 2001; Huang et al. 2002; Poulsen 2002; Shapira et al. 2002; Ton et al. 2002; Mayfield et al. 2003), yeast (Guthrie and Fink 1991; Mason et al. 1992; Wery et al. 1997; Martinez et al. 1998; Cereghino and Cregg 1999; Fischer et al. 1999; Cereghino and Cregg 2000; Cregg et al. 2000) and insects (Schmaljohn et al. 1990; Saliki et al. 1992; Jarvis et al. 1998; Altmann et al. 1999; Cha et al. 1999). In the plant system the use of plant viruses as the vehicle for the transfer for genetic material is well developed. Tobacco mosaic virus (TMV) and alfalfa mosaic virus (AMV) are two of these systems with TMV being more wildly utilized. The Ti plasmid based on the T-DNA region from *Agrobacterium tumefaciens* has been utilized for expression of heterologous DNA in many different plants such as tomato, potato, lupin, and lettuce (Kapusta et al. 1999; Walmsley and Arntzen 2000; Khandelwal et al. 2003).

SUMMARY OF THE INVENTION

It is an object of the invention to produce small interfering RNAs, which are 21-23 nucleotide long, that are specific toward an animal pathogen, such as bacteria, fungi, algae, or yeast. The RNA could be delivered as siRNA or dsRNA that is then processed into the siRNA. The siRNA or progenitor dsRNA would be produced in the cell and either delivered to the animal as the whole cell or as broken cells formulated into the diet. These diets will be fed to the animal to effect oral delivery of therapeutic siRNA specific to the target pathogen to ameliorate the disease or symptoms of the disease.

Longer nucleotides sequence up to around 1000 bases long that are complementary to the target RNA could be produced in the bacterial cell and delivered as whole cell or broken cell mixed with the diet.

It is an object of the invention to protect an animal from pathogen infection by specific degradation of pathogen encoded complementary target mRNA exploiting the RNAi phenomena.

DETAILED DESCRIPTION OF THE EMBODIMENTS

In order to fully understand the invention the following definitions are provided to clarify terms of the art that are either variously understood or currently the subject of intense research

that might change the scope of the invention if not well defined herein. For this invention the following terms are used as defined herein.

“Gene silencing” a novel gene regulatory mechanism that limits the transcript level by either suppressing transcription (known as transcriptional gene silencing) or by activating a sequence-specific RNA degradation process (posttranscriptional gene silencing).

“RNA interference” or “RNAi” a mechanism of gene silencing that limits the transcript level by a sequence-specific RNA degradation process.

“Small interfering RNA” or “siRNA” are double stranded RNAs that are less than 1000 bases

“Antisense RNA” single stranded RNA or anticoding strand of RNA serves as a template for synthesis of mRNA..

“Sense RNA” serves as a template for production of the protein or is the same sequence as the mRNA used as the template for protein synthesis.

The objects of the invention can be described by the following embodiments.

In one embodiment of the invention a siRNA is produced that is specific to an aquaculture pathogen.

In a further embodiment siRNA produced is specific to a viral aquaculture pathogen.

In a further embodiment siRNA produced is specific to viral pathogens of shrimp.

In a further embodiment siRNA produced is specific for White Spot Syndrome Virus, Yellowhead Virus, Taura Syndrome Virus, and Infectious Hypodermal and Hematopoietic Virus.

In another embodiment the siRNA is specific to viral pathogens of fish.

In a further embodiment the siRNA is specific to Infectious Salmon Anemia Virus, Infectious Pancreatic Necrosis Virus, Carp Spring Viremia Virus, grass carp reovirus, channel catfish virus, channel catfish herpes virus, marine birnavirus, Malbaricus grouper nervous necrosis virus, Dragon grouper nervous necrosis virus, rotaviruses of striped bass, smelt, Atlantic salmon and turbot, viral haemorrhagic septicaemia virus of rainbow trout, rainbow trout rhabdovirus, infectious haematopoietic necrosis virus and sleeping disease virus of rainbow trout.

It is an object of the invention to provide a method of protecting an animal from viral infection comprising the production of a viral pathogen-specific RNA in a bacterial or yeast host, processing the specific RNA containing biomass into a feed or feed supplement with no further purification, providing said feed to the animal to deliver the viral pathogen-specific RNA in an amount sufficient to inhibit the pathogenic effects of virus on the organism.

In one embodiment of the invention a method of protecting an animal from viral infection is provided. The method comprises the steps of: production of a White Spot Syndrome Virus (WSSV)-specific RNA in bacterial host, processing the biomass containing the bacteria that was used to produce the WSSV specific RNA into a feed or feed supplement with no further purification, then providing said feed to the animal to deliver the bacteria containing the WSSV-specific RNA in sufficient quantity to prevent action of the virus on the shrimp. This invention provides a rapid protection to a viral disease like white spot disease. This approach can also be applied to other types of diseases in shrimp caused by other viruses, bacteria, fungi, as well as for diseases in other aquaculture species including fish and mollusk suffering from fungal, bacterial and viral diseases. In aquatic invertebrate species, like shrimp, with "a primitive immune systems" the invention provides a method for treatment of both acute and chronic diseases via delivery of preformed RNAi molecule.

In one embodiment of the invention a method of protecting an animal from bacterial infection is provided. The method comprises the steps of production of a bacterial pathogen-specific RNA in a bacterial host, processing the biomass containing the bacteria that was used to produce the bacterial pathogen-specific RNA into a feed or feed supplement with no further purification, providing the processed biomass to the animal to deliver the bacteria containing the bacterial pathogen-specific RNA in an amount up to 1% of the total feed content.

In aquatic vertebrate species, like fish, with well-developed immune systems the invention provides a first response method to retard the onset of an acute infection threat, and eliminate chronic infection.

In further embodiments of the invention other types of expression systems, such as, yeast, algae, and fungi are used for the production of the pathogen-specific RNA. The methods used for the protection of the animal are similar to the embodiments described above.

EXAMPLES

The invention, as contemplated herein, is described in the following examples for exemplification purposes only and are not intended to limit the scope of the invention.

Example 1. Construction of recombinant plasmid containing oligonucleotides composed of between 21 and 23 nucleotides homologous to White Spot Syndrome Virus (WSSV) genes.

RNAi sequences were designed by Ambion, Inc. (Austin, Texas) using their proprietary siRNA design algorithm. RNAi sequences were designed for five genes of white spot syndrome virus (WSSV) including the genes that encode for a nucleocapsid protein VP26, a capsid protein VP 28, a ribonucleotide reductase enzyme, a DNA polymerase enzyme, and a protein that contains Kunitz protease inhibitor signature motif. All five WSSV siRNAs were designed based on the WSSV genomic sequence available in the GenBank database, accession number AF369029. In addition, siRNA was also designed for a non-structural gene and a capsid gene for the infectious hypodermal and haematopoietic necrosis virus (GenBank database, accession number AF273215); a glycoprotein gene of yellowhead virus (GenBank database, accession number AF540644); a RNA-dependent-RNA-polymerase, and a capsid protein gene, VP1 of the Taura syndrome virus (GenBank database, accession number AF277675).

The siRNA design for WSSV gene VP28 (AF369029) can be done several different ways. As designed by Ambion, one siRNA Design is based on a sense siRNA strand (5'→3') GGUUGGAUCA GGUACUUCT T and an antisense siRNA strand (5'→3') GAAGUAGCCUGAUCCAACCTC. The template design for this to use pSilencer™ siRNA expression vectors (2.0, 2.1, 3.0, & 3.1 from Ambion) is the top Strand Oligonucleotide Template 5'-GATCCGGTTG GATCAGGCTA CTTCTTCAAG AGAGAAGTAG CCTGATCAA CCTCTTTTT GGAAA-3'. With the bottom Strand Oligonucleotide Template: 5'-AGCTTTCCA AAAAAGAGGT TGGATCAGGC TACTTCTCTC TTGAAGAAGT AGCCTGATCC AACCG-3'.

A second VP28 siRNA design has a sense siRNA strand (5'→3') GGCUACUUCA AGAUGACUGT T with an antisense siRNA strand (5'→3') CAGUCAUCUU GAAGUAGCCT G. For the pSilencer vectors the top strand oligonucleotide template is 5'-GATCCGGCTA CTTCAAGATG ACTGTTCAAG AGACAGTCA TCTTGAAGTA GCCTGTTTT TGGAAA-3' while the bottom strand oligonucleotide template is 5'AGCTTTCCA AAAAACAGGC TACTTCAAGA TGACTGTCT CTTGAACAGT CATCTTGAAG TAGCC G-3'.

A third possible VP28 siRNA Design has a sense siRNA strand (5'→3') GGUGUGGAAC AACACAUCAT T and an antisense siRNA strand (5'→3') UGAUGUGUUG UUCCACACCT T. This requires a template design for pSilencer™ siRNA expression vectors having a top strand oligonucleotide template 5'-GATCCGGTGT GGAACAAACAC ATCATTCAAG AGA TGATGT GTTGTCCAC ACCTTTTG GAAA-3' with a bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAGGTGT GGAACAAACAC ATCATCTCTT GAA TGATGT GTTGTCCAC ACC G-3'.

The siRNA design for WSSV gene VP26 (AF369029) can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGGCAAAGGU AAUGUCAAUT T with an antisense siRNA Strand (5'→3') AUUGACAUUA CCUUUGGCCCT T. The template design for pSilencer™ siRNA expression vectors (2.0, 2.1, 3.0, & 3.1) has a top strand oligonucleotide template (5'→3') 5'-GATCCGGGCA AAGGTAATGT CAAT TTCAA GAGAATTGAC ATTACCTTG CCCTTTTG GAAA-3' with a bottom strand oligonucleotide template (5'→3') 5'-AGCTTTCCA AAAAA GGGC AAAGGTAATG TCAATTCTCT TGAAATTGAC ATTACCTTG CCC G-3'.

A second possible siRNA design for VP26 has a sense siRNA strand (5'→3') GGUCCUACAA UACUCCUCUT T with an antisense siRNA strand (5'→3') AGAGGAGUA UUGUAGGACC TC. This has a template design for pSilencer™ siRNA expression vectors (2.0, 2.1, 3.0, & 3.1) with a top strand oligonucleotide template 5'-GATCCGGTCC TACAATACTC CTCTTCAAG AGA AGAGGA GTATTGTAGG ACCTCTTTT TGGAAA-3' and a bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAGAGGT CCTACAATAC TCCTCTTCTC TTGAAAGAGG AGTATTGTAG GACC G-3'.

A third possible siRNA design for VP26 has a sense siRNA strand (5'→3') GGAAACAUUA AGGGAAAAT T with an antisense siRNA Strand (5'→3') UAUUUCCUU AAUGUUUCCT G. The template design for pSilencer™ siRNA vectors has a top strand oligonucleotide template 5'-GATCCGAAAC ATTAAGGGAA ATATTCAAGA GATATTCCC TTAATGTTTC CTG TTTTT GGAAA-3' with a bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAA GAAA CATTAAGGGA AATATCTCTT GAATATTCC CTTAATGTTT CC G-3'.

Another WSSV gene *ProIn* (AF369029) has a siRNA design with a sense siRNA strand (5'→3') GGGAAAGAAUU CUACAAGAAT T and an antisense siRNA strand (5'→3') UUCUUGUAGA AUUCUUCCCT G. The template design for pSilencer™ siRNA vectors has a top strand oligonucleotide template (5'→3') 5'-GATCCGGGAA GAATTCTACA AGAATTCAAG AGATTCTTGT AGAATTCTTCC CTGTTTTG GAAA-3' with a bottom strand oligonucleotide template (5'→3') 5'-AGCTTTCCA AAAAAACAGGG AAGAATTCTA CAAGAATCTC TTGAATTCTT GTAGAATTCT TCCC G-3'.

A second siRNA Design for *ProIn* has a sense siRNA strand (5'→3') GGGACCCUUU CAUGAACAT T and an antisense siRNA strand (5'→3') UGUUUCAUGA AAGGGUCCCT T. The template design for pSilencer™ siRNA vectors has a top strand oligonucleotide template 5'-GATCCGGGAC CCTTCATGA AACATTCAAG AGATGTTCA TGAAAGGGTC CC TTTTTG GAAA-3' with a bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAA GGGAC CCTTCATGA AACATCTCTT GAATGTTTC ATGAAAGGGT CCC G-3'.

A third siRNA Design for *ProIn* has a sense siRNA strand (5'→3') GGCAUACAGA UGCCUUUAT T and an antisense siRNA strand (5'→3') UAAAGGGCAU CUGUAUGCCT T. The template for pSilencer™ siRNA vectors has a top strand oligonucleotide template (5'→3') 5'-GATCC GGCAT ACAGATGCC TTTATTCAAG AGATAAAGGG CATCTGTATG CCTTTTTGG AAA-3' and bottom strand oligonucleotide template (5'→3') 5'-AGCTTTCC AAAAAA GGCA TACAGATGCC CTTTATCTCT TGAATAAAGG GCATCTGTAT GCC G-3'.

Another potential gene for RNA interference is the white spot virus Rr092 gene (AF369029). A possible siRNA design for *Rr092* has a sense siRNA strand (5'→3') GGAAGAUUCA UCUGUUCGAT T and an antisense siRNA strand (5'→3') UCGAACAGAU GAAUCUUCCT G. The template design for pSilencer™ siRNA vectors has a top strand oligonucleotide template (5'→3') 5'-GATCC GAAGA TTCATCTGTT CGATTCAAGA GATCGAACAG ATGAATCTTC CTG TTTTG AAA-3' and bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAA CAGG AAGATTCAATC TGTCGATCT CTTGAATCGA ACAGATGAAT CTTCC G-3'.

A second potential siRNA Design for Rr092 has a sense siRNA strand (5'→3') GGACAUAGAUU AUGCGUGUGT T and an antisense siRNA strand (5'→3') CACACGCAUA AUCAUGUCCT G. The template design for pSilencer™ siRNA vectors has a top strand oligonucleotide template 5'-GATCCGGACA TGATTATGCG TGTGTTCAAG AGACACACGC ATAATCATGT CCTGTTTTT GGAAA-3' and a bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAACAGGA CATGATTATG CGTGTGTCTC TTGAACACAC GCATAATCAT GTCC G-3'.

A third potential siRNA design for *Rr092* has a sense siRNA strand (5'→3') GGAUACCAUC AAUAGAAAGT T and an antisense siRNA strand (5'→3') CUUUCUAUUG AUGGUAU CCT T. Template design for pSilencer™ siRNA vectors with a top strand oligonucleotide template 5'-GATCCGGATA CCATCAATAG AAAGTTCAAG AGACTTTCTA TTGATGGTAT CCTTTTTGG AAA-3' and a bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAAGGATA CCATCAATAG AAAG TCTCT TGAACTTCT ATTGATGGTA TCC G-3'.

Another WSSV gene that could be regulated by RNAi is the DNAPol (AF369029) gene. A potential siRNA design for *DNAPol* has a sense siRNA strand (5'→3') GGAAGUGGUC AUCUACGACT T with an antisense siRNA strand (5'→3') GUCGUAGAUG ACCACUU CCT T. Template design for pSilencer™ siRNA vectors has a top strand oligonucleotide template (5'→3') 5'-GATCCGGAAG TGGTCATCTA CGACTTCAAG AGAGTCGTAG ATGACCAC TT CCTTTTTGG AAA-3' and a bottom strand oligonucleotide template (5'→3')

5'-AGCTTTCCA AAAAAGGAAG TGGTCATCTA CGACTCTCTT GAAGTCGTAG
ATGACCACTT CC G-3'

A second siRNA Design for *DNAPol* has a sense siRNA Strand (5'→3')

GGAAGAACAU GAAACUGUCT T and an antisense siRNA strand (5'→3') GACAGUUUCA
UGUUCUUCCT T. Template design for pSilencer™ siRNA vectors has a top strand
oligonucleotide template 5'-GATCCGGAAAG AACATGAAAC TGTC TTCAA
GAGAGACAGT TTCATGTTCT TCCTTTTG GAAA-3' and a bottom strand
oligonucleotide template 5'-AGCTTTCCA AAAAAGGAAG AACATGAAAC
TGTCTCTCTT GAAGACAGTT TCATGTTCTT CC G-3'.

A third design for siRNA for *DNAPol* has a sense siRNA strand (5'→3')

GGAGCAUUGU CAUUUAAUAT T with an antisense siRNA strand (5'→3') UAUUAAAUGA
CAAUGCUCCT C. Template design for pSilencer™ siRNA vectors has a top strand
oligonucleotide template 5'-GATCCGGAGC ATTGTCATT AATA TTCAAAG
AGATATTAAA TGACAATGCT CCTCTTTTT GGAAA-3' and a bottom strand
oligonucleotide template 5'-AGCTTTCCA AAAAA GAGGA GCATTGTCAT
TTAATATCTC TTGAATATTA AATGACAATG CTCC G-3'.

Oligonucleotides of 21-23-mer specific for the following five WSSV genes are custom designed and synthesized: a ribonucleotide reductase, a protease inhibitor, a DNA polymerase gene, a nucleocapsid gene (VP26) and a capsid gene (VP28). The synthesis of sense and antisense oligonucleotides representing these genes are based on the published sequence of the WSSV genome, GenBank accession number AF369029 (van Hulsen et al. 2001). Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and are cloned into a plasmid vector such as L4440 (Kamath et al. 2002) or one of the commercially available plasmids (e.g., pSIREN-DNR from Clonetech or pSILENCER from Ambion). The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase and lacking double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying WSSV specific genes are sequenced to confirm the identity of the clones. Alternative clones can be made based on different strains of the WSSV such as that described by Yang and colleagues (Yang et al. 2001).

Example 2. Bacterial induction for the expression of WSSV dsRNA and formulation of feed.

Escherichia coli strain HT₁₁₅DE₃ carrying IPTG inducible WSSV gene are grown in LB medium containing ampicillin, then induced with IPTG for the expression of WSSV-specific RNA. IPTG induction is empirically optimized to obtain maximum induction of dsRNA expression. Bacterial biomass containing cells which express the WSSV gene or genes are mixed with shrimp feed in a microbound format in beads composed of alginate and starch in a polymeric form. Alternative microbound forms are available such as polylactide (Bootland et al. 2002), carrageen , alginate (Sultana et al. 2000; Byon et al. 2002; Harel 2003), and chitosan (Vournakis et al. 2001). Attractants are added to make the beads more palatable to the target species (in the case of shrimp, krill meal would be a good attractant).

Example 3. Method for protection of shrimp from WSSV infection.

Shrimp are fed either a control diet or a diet containing bacterial biomass containing WSSV-specific dsRNA (Example 2). Animals are challenged with WSSV, and their survivability in response to viral infection is measured. The WSSV load in the control and treatment samples is measured by real-time PCR following published protocol (Dhar et al. 2001). The mRNA expression of the five WSSV target genes is measured in the treated and control animals using real-time RT-PCR to determine the difference in expression in two treatment groups following a published method (Dhar et al. 2003).

Example 4. Construction of recombinant plasmid containing oligonucleotides of between 21 and 23 nucleotides homologous to Infectious hematopoietic necrosis virus (IPNV) genes.

RNAi sequences were designed by Ambion, Inc. (Austin, Texas) using their proprietary siRNA design algorithm. siRNA was also designed for a non-structural gene and a capsid gene for the infectious hypodermal and haematopoietic necrosis virus (GenBank database, accession number AF273215). Oligonucleotides of 21-23-mer specific for the following two IPNV genes

are custom designed and synthesized: capsid proteins VP2 and VP3. The synthesis of sense and antisense oligonucleotides representing these genes is based on published sequence of the IPNV genome, GenBank accession number AY283780 (Zhang & Suzuki, unpublished). Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and are cloned into a plasmid vector L4440 (Kamath et al. 2002) . The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase and lacking double-strand-specific RNase III) (Kamath et al. 2002) . The recombinant clones carrying IPNV-specific genes are sequenced to confirm the identity of the clones.

Example 5. Bacterial induction for the expression of IPNV dsRNA and formulation of feed.

Escherichia coli strain HT₁₁₅DE₃ carrying IPTG inducible IPNV gene(s) are grown in LB medium containing ampicillin, and the induced with IPTG for the expression of IPNV-specific RNA. IPTG induction will be empirically optimized to obtain maximum induction of dsRNA expression. Bacterial biomass containing cells expressing IPNV gene(s) is mixed with shrimp feed in a microbound format in beads composed of alginate and starch in a polymeric form. Alternative microbound forms are available such as polylactide (Bootland et al. 2002), carrageen, alginate, and chitosan. Attractants are added to make the beads more palatable to the target species (in the case of fish, fishmeal is a good attractant).

Example 6. Method for protection of salmonids from IPNV infection

Rainbow trout are fed either a control diet or a diet containing bacterial biomass containing IPNV-specific dsRNA (Example 5). Animals are challenged with IPNV, and their survivability in response to viral infection is measured. The IPNV load in the control and treatment samples will be measured by real-time PCR following a protocol similar to that used for WSSV in shrimp (Dhar et al. 2001). The mRNA expression of the two IPNV target genes is measured in the treated and control animals using real-time RT-PCR to determine the difference in expression in two treatment groups following a protocol similar to measuring cellular gene expression in shrimp (Dhar et al. 2003).

Example 7. Construction of recombinant plasmid containing oligonucleotides of between 21 and 23 nucleotides homologous to ISAV genes.

Oligonucleotides of 21-23-mer specific for the following two ISAV genes are custom designed and synthesized: hemagglutinin (HA) and glycoprotein P3. The synthesis of sense and antisense oligonucleotides representing these genes is based on published sequence of the ISAV genome, GenBank accession numbers AF309075 (Krossoy et al. 2001) and AJ514403 (Snow et al. 2003). Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and are cloned into a plasmid vector L4440 (Kamath et al. 2002). The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase and lacking double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying these ISAV-specific genes are sequenced to confirm the identity of the clones.

Example 8. Bacterial induction for the expression of ISAV dsRNA and formulation of feed.

Escherichia coli strain HT₁₁₅DE₃ carrying IPTG inducible ISAV genes (Example 7) are grown in LB medium containing ampicillin, and are induced with IPTG for the expression of ISAV-specific RNA. IPTG induction is empirically optimized to obtain maximum induction of dsRNA expression. Bacterial biomass expressing HA and/or glycoprotein P3 genes is mixed with salmonid feed in a microbound format in beads composed of alginate and starch in a polymeric form. Alternative microbound forms are available, such as polylactide (Bootland et al. 2002), carrageen, alginate, and chitosan. Attractants are added to make the beads more palatable to the target species (in the case of salmon, AquaSavor® is a good attractant).

Example 9. Method for protection of salmonids from ISAV infection

Salmonids, such as salmon and rainbow trout, are fed either a control diet or a diet containing bacterial biomass containing ISAV-specific dsRNA (Example 8). Animals are challenged with ISAV, and their survivability in response to viral infection is measured. The ISAV load in the control and treatment samples is measured by real-time PCR following a

method similar to that used for WSSV (Dhar et al. 2001). The mRNA expression of the two ISAV target genes (HA and glycoprotein P3) is measured in the treated and control animals using real-time RT-PCR to determine the difference in expression in two treatment groups following a method similar to that used for WSSV (Dhar et al. 2003).

Example 10. Construction of recombinant plasmid containing oligonucleotides between 21 and 23 nucleotides complementary to Carp Spring Virema genes.

Spring viremia of carp, caused by the spring viremia of carp virus (SVCV), is one of the important viral diseases of common carp. The disease is wide spread in European and Asian carp culture (Ahne et al. 2002). Carp infected with SVCV show tissue destruction in kidney, spleen, and liver leading to hemorrhage, loss of water-salt balance and impairment of immune response (Ahne et al. 2002). The SVCV genome contains a single molecule of linear, negative-sense, single stranded RNA encoding nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and RNA dependent RNA polymerase (L) with a short leader and trailer sequence in 3'→5' direction (Hoffman et al. 2002).

Oligonucleotides of 21-23-mer specific for these five SVCV genes (N, P, M, G, and L) are custom designed and synthesized based on the published sequence of SVCV genome, GenBank accession number AJ318079 (Hoffman et al. 2002). Sense and antisense oligonucleotides are annealed to generate double stranded DNA, and cloned into a plasmid vector L4440 (Kamath et al. 2002). *Escherichia coli* strain HT115DE3 (carrying IPTG inducible expression of T7 polymerase, and lacks double-strand-specific RNase III) are transformed using the plasmid (Kamath et al. 2002). The recombinant clones carrying SVCV specific genes are sequenced to confirm the identity of the clones.

Example 11. Bacterial induction for the expression of Carp Spring Virema dsRNA and formulation of feed.

Escherichia coli strain HT₁₁₅DE₃ carrying IPTG inducible SVCV genes are grown in LB medium containing ampicillin, and induced with IPTG for the expression of SVCV-specific RNA. IPTG induction is empirically optimized to obtain maximum induction of dsRNA

expression. Bacterial cells expressing SVCV gene are mixed with carp feed in a microbound format in beads composed of alginate and starch in a polymeric form and attractants are added to make the beads palatable to carp.

Example 12. Fungal induction for the expression of Carp Spring Virema dsRNA, and formulation of feed.

A deletion mutant is made or a strain is used that lacks dsRNase activity. The fungus used can be chosen either from the fungi imperfecti (yeast such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe* (Raponi and Arndt 2003) or *Phaffia rhodozyma*) or the filamentous fungi (e.g., *Neuroporsa crassa*) (Buxton et al. 1990). Strains of *P. rhodozyma* are already known that have dsRNA present that is associated with a viral infection (Castillo and Cifuentes 1994). For the purposes of this example a dsRNase deficient mutant of *S. cerevisiae* will be constructed using standard molecular techniques to knockout dsRNase identified with the published yeast genome. This will then be transformed with a vector such as pESC-URA (Stratgene). The main function that needs to be present in the transformation vector is the presence of two strong promoters that can coexpress RNAs that are complementary to each other. The pESC-URA vector will be modified to contain two pieces of DNA that are specific for spring carp viremia dsRNA using methods similar to those described in Examples 1 & 2. The yeast will be made competent and then transformed as described in the Stratgene users' manual which is a standard molecular biological technique (Ausubel et al. 1997). Auxotrophic selection will be used and strains that grow on uracil will contain vector. The yeast mutants will be amplified in a galactose medium to drive the two promoters (Gal1 and Gal10) that are provided in the pESC vectors for insertion of the two sequences. The yeast can then be used as a source of dsRNA specific to SVCV. The yeast can be provided as biomass directly added to the feed or microencapsulated and mixed into the feed to prevent infection.

Example 13. Method for protection of salmonids from Spring Viremia of Carp Virus infection

Carp is fed either control diet or diet containing bacteria (Example 11) or fungi (Example 12) expressing dsRNA representing N, P, M, G, and L genes of SVCV. Animals are challenged using SVCV contaminated water since waterborne transmission is believed to be the primary route of infection for SVCV (Ahne et al. 2002). After SVCV challenge, animals are maintained at 10 to 17°C temperature because high mortality occurs at that temperature. The survivability in response to SVCV challenge is recorded and the SVCV load in the control and treatment samples is measured by real-time RT-PCR.

Example 14. Construction of recombinant plasmid containing 21-23 nucleotides of *Streptococcus iniae* gene.

S. iniae is an important bacterial pathogen of fish infecting salmonid, tilapines, channel catfish, zebrafish among many other fishes worldwide (Zlotkin et al. 1998; Shoemaker et al. 2001; Neely et al. 2002). In addition to fish, *S. iniae* has also been reported to infect human in North America and Asia (Weinstein et al. 1997; Lau et al. 2003). In aquaculture farms, antibiotics are routinely used to control *S. iniae* infection. Due to growing concerns regarding widespread use of antibiotics in farm raised terrestrial and aquatic animals, there is an urgent need to develop alternative means of controlling the bacterial diseases. Towards this end, the current invention provides a solution in controlling *S. iniae* as well as other bacterial disease infection in fish.

Oligonucleotides of 21-23-mer specific for *S. iniae* cytolysin and lactate oxidase genes are custom designed and synthesized based on published *S. iniae* sequence (Gibello et al. 1999; Fuller et al. 2002). Cytolysin is a functional homologue of streptolysin produced by group A streptococcus, and cytolysin expression is required for local tissue necrosis (Fuller et al. 2002). Lactate oxidase genes, on the other hand, are involved in l-lactic acid metabolism in *S. iniae*. Sense and antisense oligonucleotides representing cytolysin and lactate oxidase genes are annealed to generate double stranded DNA, and cloned into a plasmid vector L4440 before transforming *Escherichia coli* strain HT115DE3 (carrying IPTG inducible expression of T7 polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying *S. iniae* genes are sequenced to confirm the identity of the recombinant clones.

Example 15. Bacterial induction for the expression of *Streptococcus iniae* dsRNA, and formulation of feed.

Escherichia coli strain HT115DE3 carrying IPTG inducible *S. iniae* genes are grown in LB medium containing ampicillin, and induced with IPTG for the expression of *S. iniae* specific RNA. The expression of dsRNA is empirically optimized by varying the IPTG concentration in the bacterial media. Bacterial cells expressing *S. iniae* gene are mixed with fish diet in a microbound format in beads composed of alginate and starch in a polymeric form and attractants are added to make the beads palatable to fish.

Example 16. Method for protection of fish from infection by *Streptococcus iniae*.

Striped bass are fed either control diet or diet containing bacteria expressing *S. iniae* dsRNA. Striped bass are challenged with *S. iniae*. The survivability in response to *S. iniae* challenge is then recorded in the control and treated fish.

Example 17. Construction of recombinant plasmid containing 21-23 nucleotides of porcine parvovirus (PPV), a pathogen of pigs.

Oligonucleotides of 21-23-mer specific for the VP1 capsid protein gene of PPV are custom designed and synthesized. The synthesis of sense and antisense oligonucleotides representing these genes is based on the published sequence of the porcine parvovirus genome, GenBank accession number NC001718 (Bergeron et al. 1993). The major antigenic epitopes of PPV are in the VP2 capsid gene, which is chosen for this design (Kamstrup et al. 1998). Sense and antisense oligonucleotide sequences are annealed to generate double stranded DNA, and are cloned into a plasmid vector L4440 (Kamath et al. 2002). The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying PPV specific genes are sequenced to confirm the identity of the clones. These siRNAs are then formulated into feeds and are used for the treatment of pigs to prevent PPV

infection using methods described in the previous examples for other animals (Examples 2 and 3).

Example 18. Construction of recombinant plasmid containing 21-23 nucleotides of Exotic Newcastle disease, a viral pathogen of chickens.

Oligonucleotides of 21-23-mer specific for the ENDV capsid protein gene are custom designed and synthesized. The synthesis of sense and antisense oligonucleotides representing these genes is based on published sequence of the canine parvovirus genome, GenBank accession number NC002617 (Sellers and Seal 2000) . Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and cloned into a plasmid vector such as L4440 (Kamath et al. 2002) that contains two promoters for production of RNA. The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002) . The recombinant clones carrying CPV specific genes are sequenced to confirm the identity of the clones. These siRNAs are then formulated into feeds and used for the treatment of chickens to prevent ENDV infection using methods described in the previous examples for other animals (see Example 15 for example).

Example 19. Construction of recombinant plasmid containing oligonucleotides of between 21 and 23 nucleotides long complementary to foot and mouth disease (FMD), a viral pathogen of cows.

Oligonucleotides of 21-23-mer specific for the VP1 capsid protein gene are custom designed and synthesized. The synthesis of sense and antisense oligonucleotides representing these genes is based on published sequence of the canine parvovirus genome, GenBank accession number NC 004915 (Saravanan et al. 2003). Alternative sequences for various strains could be used in parallel to provide a broader protection than this single strain of FMD. Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and cloned into a plasmid vector L4440 (Kamath et al. 2002) . The recombinant plasmid are used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7

polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying CPV specific genes are sequenced to confirm the identity of the clones. These siRNAs are then formulated into feeds and used for the treatment of cows to prevent CPV infection using methods described in the previous examples for other animals (see Examples 15).

Example 20. Construction of recombinant plasmid containing 21-23 nucleotides of feline leukemia virus (FeLV), a viral pathogen of cats.

Oligonucleotides of 21-23-mer specific for an envelope protein gene are custom designed and synthesized. The synthesis of sense and antisense oligonucleotides representing this gene is based on published sequence of the FeLV segment containing envelope protein genes, GenBank accession number AF403716 (Anderson et al. 2001). Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and are cloned into a plasmid vector L4440 (Kamath et al. 2002). The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying FeLV-specific genes are sequenced to confirm the identity of the clones. These siRNAs are then formulated into feeds and are used for the treatment of cats to prevent FeLV infection, using methods analogous to those described in the previous examples for other animals (Examples 2 and 3).

Example 21. Construction of recombinant plasmid containing 21-23 nucleotides of canine parvovirus (CPV), a viral pathogen of dogs.

Oligonucleotides of 21-23-mer specific for the VP1 capsid protein gene are custom designed and synthesized. The synthesis of sense and antisense oligonucleotides representing these genes is based on published sequence of the canine parvovirus genome, GenBank accession number NC001539 (Reed et al. 1988). The N-terminal region of VP1 is chosen for this design since it has been shown to affect nuclear transport of capsids and efficient infection by this virus (Vihinen-Ranta et al. 2002). Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and are cloned into a plasmid vector L4440 (Kamath

et al. 2002). The recombinant plasmid is used to transform *Escherichia coli* strain HT₁₁₅DE₃ (carrying IPTG inducible expression of T7 polymerase, and lacks double-strand-specific RNase III) (Kamath et al. 2002). The recombinant clones carrying CPV-specific genes are sequenced to confirm the identity of the clones. These siRNAs are then formulated into feeds and are used for the treatment of dogs to prevent CPV infection, using methods analogous to those described in the previous examples for other animals (Examples 2 and 3).

Example 22. Construction of recombinant plasmid containing 21-23 nucleotides of White Spot Syndrome Virus (WSSV) genes for expression in plants.

Oligonucleotides of 21-23-mer specific for the following five WSSV genes are custom designed and synthesized, sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA as described in Example 1. For use in plant systems, a different plasmid is used based on the T-DNA region of the *Agrobacterium* Ti plasmid. A large number of these plasmids are available which are appropriate for their use in a variety of plant species (insert references). The annealed dsDNA is cloned into a plasmid vector having two promoters on opposite strands such as the lac, trp, or PL promoters using standard methods to both construct the plasmid and to produce the construct (Clark 1997). The recombinant plasmid is used to transform alfalfa cells (Taschner et al. 1994; Lerrick et al. 2001; Kelemen et al. 2002). The recombinant callus culture carrying WSSV-specific genes are sequenced to confirm the identity of the clones. Callus is used to regenerate genetically engineered plants expressing the WSSV-specific RNA. The plant material is dried gently by air-drying then incorporated in feeds and used for protection of shrimp against WSSV infection in methods analogous to those in Examples 2 & 3.

Example 23. Alternative feed formulation using top coating.

Top coating of feeds with biomass is done using standard feed technology wherein the biomass containing the biomass as described in the examples above (e.g., Examples 2, 5, 8, 11, & 12) is top coated on an existing feed and fed to provide the desired regulation of activity.

Example 24. Taura syndrome virus siRNA design.

RNAi designs for Taura syndrome virus (TSV) *RdRp* gene (AF277675) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAGUGUCUA AUGCGGAGAT T and an antisense siRNA strand (5'→3') UCUCCGCAUU AGACACUCCT G. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGAGT GTCTAATGCG GAGATTCAAG AGATCTCCGC ATTAGACACT CCTGTTTTT GGAAA-3'. with the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAA CAGGA GTGTCTAATG CGGAGATCTC TTGAATCTCC GCATTAGACA CTCC G-3'.

Another RNAi design for Taura syndrome virus (TSV) *RdRp* gene (AF277675) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGGAAAGAGCG GAAAGCAGAT T and an antisense siRNA strand (5'→3') UCUGCUUUCC GCUCUUCCT T. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGGAA GAGCGGAAAG CAGATTCAAG AGATCTGCTT TCCGCTCTTC CCTTTTTGG AAA-3'. with the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAA GGGAA GAGCGGAAAG CAGATCTCTT GAATCTGCTT TCCGCTCTTC CC G-3'.

Another RNAi design for Taura syndrome virus (TSV) *RdRp* gene (AF277675) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAAUUCAUU GUUGACAACT T and an antisense siRNA strand (5'→3') GUUGUCAACA AUGAAUUCCT C. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGAAT TCATTGTTGA CAACTTCAAG AGAGTTGTCA ACAATGAATT

CCTTTTTT GGAAA-3'. with the bottom strand oligonucleotide template as 5'-AGCTTTCCA AAAAAGAGGA ATTCAATTGTT GACAACTCTC TTGAAGTTGT CAACAATGAA TTCC G-3'.

RNAi designs for Taura syndrome virus (TSV) *vp1* gene (AF277675) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAAUUGGAUG AGAUGUCUAT T and an antisense siRNA strand (5'→3') UAGACAUUCUC AUCCAAUCCT T. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGATT GGATGAGATG TCTATTCAAG AGATAGACAT CTCATCCAAT CCTTTTTGG AAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAGGATT GGATGAGATG TCTATCTCTT GAATAGACAT CTCATCCAAT CC G-3'

Another RNAi design for Taura syndrome virus (TSV) *vp1* gene (AF277675) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGUACGCUUG CUAAAGCAGT T and an antisense siRNA strand (5'→3') CUGCUUUAGC AAGCGUACCT G. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGTAC GCTTGCTAAA GCAGTTCAAG AGACTGCTTT AGCAAGCGTA CCTGTTTTT GGAAA-3'. with the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAA CAGGT ACGCTTGCTA AAGCAGTCTC TTGAAGTGCT TTAGCAAGCG TACC G-3'.

Another RNAi design for Taura syndrome virus (TSV) *vp1* gene (AF277675) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAAUACGAAG GUGUCUUUGT T and an antisense siRNA strand (5'→3') CAAAGACACC UUCGUAUCCT G. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGATA CGAAGGTGTC TTTGTTCAAG AGACAAAGAC ACCTTCGTAT CCTGTTTTT GGAAA-3'. with the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAA CAGGA TACGAAGGTG TCTTTG TCT CTTGAACAAA GACACCTTCG TATCC G-3'.

Example 25. siRNA design for yellow head virus of shrimp.

RNAi designs for Yellow head virus (YHV) structural glycoprotein gene *YHVgp* (AF540644) that could be regulated by RNAi can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGCUCGCAUA UCAUUUAUAT T and an antisense siRNA strand (5'→3') UAUAAAUGAU AUGCGAGCCT G. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCCGGCTC GCATATCATT TATATTCAAG AGATATAAAAT GATATGCGAG CCTGTTTTT GGAAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAACAGGC TCGCATATCA TTTATATCTC TTGAATATAA ATGATATGCG AGCC G-3'.

Another RNAi design for Yellow head virus (YHV) structural glycoprotein gene *YHVgp* (AF540644) can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAUAUCCUC CCGCCAACAT T and an antisense siRNA strand (5'→3') UGUUGGCGGG AGGAUAUCCT T. The template design for this to use pSilencer™ siRNA vectors has the top strand oligonucleotide template 5'-GATCC GGATA TCCTCCGCC AACATTCAAG AGATGTTGGC GGGAGGATAT CCTTTTTGG AAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAA GGATA TCCTCCGCC AACATCTCTT GAATGTTGGC GGGAGGATAT CC G-3'.

Another RNAi design for Yellow head virus (YHV) structural glycoprotein gene *YHVgp* (AF540644) can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGUCUUUGUU AUGAAGUAGT T and an antisense siRNA strand (5'→3') CUACUUCAUA ACAAAAGACCT T. The template design for this to use pSilencer™ siRNA vectors is the top strand oligonucleotide template 5'-GATCC GGTCT TTGTTATGAA GTAGTTCAAG AGACTACTTC ATAACAAAGA CCTTTTTGG AAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAGGTCT TTGTTATGAA GTAGTCTCTT GAACTACTTC ATAACAAAGA CC G-3'.

Example 26. Infectious hypodermal and hematopoietic necrosis virus (IHHNV) siRNA design.

The siRNA design for Infectious hypodermal and hematopoietic necrosis virus (IHHNV) gene *orf1* (AF273215) can be done several different ways. As designed by Ambion one siRNA Design is based on a sense siRNA strand (5'→3') GGACAUACUG CAUACACGUT T and an antisense siRNA strand (5'→3') ACGUGUAUGC AGUAUGUCCT T. The template design for this to use pSilencer™ siRNA expression vectors (2.0, 2.1, 3.0, & 3.1 from Ambion) is the top Strand Oligonucleotide Template 5'-GATCCGGACA TACTGCATAC ACGTTCAAG AGAACGTGTA TGCAGTATGT CCTTTTTGG AAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAA GGACA TACTGCATAC ACGTTCTCTT GAAACGTGTA TGCAGTATGT CC G-3'.

A second siRNA design for IHHNV gene *orf1* (AF273215) can be done several different ways. As designed by Ambion one siRNA Design is based on a sense siRNA strand (5'→3') GGUCCAAAUC AAGACCCUAT T and an antisense siRNA strand (5'→3') UAGGGUCUUG AUUUGGACCT G. The template design for this to use pSilencer™ siRNA vectors is the top strand oligonucleotide template 5'-GATCC GGTCC AAATCAAGAC CCTATTCAAG AGATAAGGGTC TTGATTGGA CCTGTTTTT GGAAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAACAGGT CCAAATCAAG ACCCTATCTC TTGAATAGGG TCTTGATTG GACC G-3'.

A third siRNA design for IHHNV gene *orf1* (AF273215) can be done several different ways. As designed by Ambion one siRNA Design is based on a sense siRNA strand (5'→3') GGACAAUAUA AAGACAAACT T and an antisense siRNA strand (5'→3') GUUUGUCUUU AUAUUGUCCT C. The template design for this to use pSilencer™ siRNA vectors is the top strand oligonucleotide template 5'-GATCCGGACA ATATAAAGAC AAACATTCAAG AGAGTTGTC TTTATATTGT CCTCTTTTT GGAAA-3'. With the bottom strand

oligonucleotide template 5'-AGCTTTCCA AAAAAGAGGA CAATATAAAG
 ACAAACTCTC TTGAAGTTG TCTTATATT GTCC G-3'.

Another gene that could be regulated by RNAi design for IHHNV gene *orf2* (AF273215) can be done several different ways. As designed by Ambion one siRNA Design is based on a sense siRNA strand (5'→3') GGAUCAAGUG GACCAGACCT T and an antisense siRNA strand (5'→3') GGUCUGGUCC ACUUGAU CCT T. The template design for this to use pSilencer™ siRNA vectors is the top strand oligonucleotide template 5'-GATCCGGATC AAGTGGACCA GACCTTCAAG AGAGGTCTGG TCCACTTGAT CCTTTTG AAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAGGATC AAGTGGACCA GACCTCTCTT GAAGGTCTGG TCCACTTGAT CC G-3'.

Another RNAi design for IHHNV gene *orf2* (AF273215) can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAGGCACAU CAUUUGAGAT T and an antisense siRNA strand (5'→3') UCUCAAAUGA UGUGCCUCCT G. The template design for this to use pSilencer™ siRNA vectors is the top strand oligonucleotide template 5'-GATCCGGAGG CACATCATT GAGATTCAAG AGATCTCAA TGATGTGCCT CCTGTTTT GGAAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAACAGGA GGCACATCAT TTGAGATCTC TTGAATCTCA AATGATGTGC CTCC G-3'.

Another RNAi design for IHHNV gene *orf2* (AF273215) can be done several different ways. As designed by Ambion one siRNA design is based on a sense siRNA strand (5'→3') GGAUACUACUGGACUACAU TT and an antisense siRNA strand (5'→3') AUGUAGUCCAGUAGUAUCCTT. The template design for this to use pSilencer™ siRNA vectors is the top strand oligonucleotide template 5'-GATCCGGATA CTACTGGACT ACATTCAAG AGAATGTAGT CCAGTAGTAT CCTTTTG AAA-3'. With the bottom strand oligonucleotide template 5'-AGCTTTCCA AAAAAGGATA CTACTGGACT ACATTCTCTT GAAATGTAGT CCAGTAGTAT CC G-3'.

Example 27. Cloning of siRNA in bacterial plasmid vector:

Sense and antisense oligonucleotide sequence are annealed to generate double stranded DNA, and will be cloned into a pET Directional TOPO™ Expression vector (Invitrogen, Inc., Carlsbad, California) or pCX-TOPO PurePro™ *Caulobacter* plasmid expression vector (Invitrogen, Inc.) or L4440 plasmid vector (Kamath et al. 2002). The recombinant plasmid will be used to transform *Escherichia coli* strain BL21 Star™ (DE3) One Shot Chemically Competent cells (Invitrogen, Inc.) or *Caulobacter crescentus* cells or *Escherichia coli* HT₁₁₅DE₃ cells (Kamath et al. 2001), respectively. The recombinant clones will be sequenced to confirm the identity of the clones. Clones that contain virus-specific genes will be grown in LB medium containing ampicillin and IPTG. The concentration of IPTG will be empirically determined to obtain maximum expression of siRNA. Bacterial biomass containing cells which express siRNA will be mixed with shrimp feed in a microbound format in beads composed of alginate and starch in a polymeric form. Attractants such as krill meal will be added to the feed to make it more palatable to shrimp.

Example 30. Diseases of aquatic and terrestrial animals:Diseases of aquatic animals

Protozoa

Amyloodinium ocellatum (dinoflagellate)

Brooklynella hostilis (ciliate)

Cryptocaryon irritans (ciliate)

Ichthyophthirius multifilis (Ich – a ciliate)

Chilodonella cyprini (a ciliate)

Hexamita (a flagellate)

Microsporea

Glugea, Spraguea spp.

Myxosporia

Henneguya spp.

Myxobolus spp.

Platyhelminthes

Monogenea (trematode)

Digenea (trematodes)

Cestoda (tapeworms)

Nematoda

Cappalaria (Eimeria spp.)

Crustacea

Argulus spp. (Brachyuran)

Lepeophtheirus salmonis (Salmon lice – a copepod)

Learnea spp. (Acanthocephalan)

Sporozoa

Coccidia spp.

Fungi

Saprolegnia parasitica (an oomycete)

Aphanomyces astaci (an oomycete)

Ichthyophonus hoferi (fungus-like agent)

Fusarium solani (a hyphomycete)

Exophiala salmonis (a hyphomycete)

Diseases of terrestrial animals

African horse sickness virus (equine)

African swine fever virus (porcine)

Aujeszky's disease virus (porcine herpesvirus 1)

Avian influenza viruses (poultry)

Babesia caballi and B. equi (equine)
Bacillus anthracis (all)
Bluetongue virus (cattle, sheep, goats, deer)
Brucella melitensis (bovine)
Brucella ovis (ovine)
Brucella suis (porcine)
Burkholderia (Pseudomonas) mallei equine)
Classical swine fever virus (porcine)
Cochliomyia hominivorax (ovines, bovines)
Eastern and western equine encephalomyelitis viruses (equine)
Echinococcus multilocularis and E. granulosus (canine)
Equine infectious anaemia virus (equine)
Foot and mouth disease virus (ovine, bovine)
Histoplasma farciminosum (fungus-like many species)
Horse pox virus (equine)
Mycoplasma agalactiae (bovine, ovine)
Mycoplasma mycoides mycoides
Mycoplasma mycoides var Capri (caprine)
Newcastle disease virus (avian)
Peste de petits ruminants virus
Rabies virus and rabies related viruses as follows:

Duvenhage
Lagos bat
Mokola
European bat lyssaviruses I and II.

Rift Valley Fever virus
Rinderpest virus (ovine, bovine, caprine)
Sheep and goat pox virus

Swine vesicular disease
Teschen disease virus
Theileria annulata (ovine, bovine)
Trichinella spiralis (porcine) a protozoan
Trypanosoma equiperdum, T. evansi & T. theileri (Protozoans)
Venezuelan equine encephalomyelitis virus (equine)
Vesicular stomatitis virus (porcine)
Brucellosis
Chronic Wasting Disease
Equine Infectious anemia
Equine viral arteritis
Johnes
Psedorabies
Scrapie
Tuberculosis

The foregoing is a non-exhaustive list of disorders and disorder-causing agents that can be treated or inhibited using the methods and compositions described herein.

The disclosure of every patent, patent application, and publication cited herein is hereby incorporated herein by reference in its entirety.

While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention can be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims include all such embodiments and equivalent variations.

We claim:

1. A feed, feed supplement, or therapeutic composition comprising siRNA or dsRNA, such siRNA or dsRNA being expressed in an organism, and capable of being processed into siRNA that inhibit an animal pathogen.
2. The feed, feed supplement, or therapeutic composition of claim 1, wherein said pathogen is a virus, bacteria, or fungi.
3. The feed, feed supplement, or therapeutic composition of claim 2, wherein said virus is selected from White Spot Syndrome Virus, Taura Syndrome Virus, Yellow Head Virus, and Infectious Hypodermal and Hematopoietic Virus.
4. The feed, feed supplement, or therapeutic composition of claim 2, wherein said virus is selected from porcine parvovirus (PPV), exotic necastle disease, foot an mouth disease (FMD), feline leukemia virus (FLV), canine parvovirus.
5. The feed, feed supplement, or therapeutic composition of claim 2, where said bacterium is selected from aquacultural or agricultural bacterial pathogens.
6. The feed, feed supplement, or therapeutic composition of claim 5, wherein said aquacultural bacterial pathogen is selected from *Aeromonas spp.*, *Edwardsiella spp.*, *Flavobacterium spp.*, *Flexibacter spp.*, *Mycobacterium sp.*, *Streptococcus spp.*, *Salmonella spp.*, *Vibrio spp.*, and *Yersinia reuckeri*.
7. The feed, feed supplement, or therapeutic composition of claim 5, wherein said agricultural bacterial pathogen is selected from *Mycobacterium spp.*, *Enterococcus spp.*, *Streptococcus spp.*, *Salmonella spp.*, and *Yersinia pestis*.
8. The feed, feed supplement, or therapeutic composition of claim 2, wherein said fungus is selected from aquacultural or agricultural fungal pathogens.
9. The feed, feed supplement, or therapeutic composition of claim 8, wherein said aquacultural fungal pathogen is selected from *Oomycetes* fungi, *Aphanomyces astaci*, and *Ichthyophonus spp.*

10. The feed, feed supplement, or therapeutic composition of claim 8, wherein said agricultural fungal pathogen is selected from *Trychophyton spp.*, *Fusarium solani*, and *Candida spp.*
11. The feed, feed supplement, or therapeutic composition of claim 1, wherein said pathogen is a eukaryote.
12. The feed, feed supplement, or therapeutic composition of claim 10, wherein said eukaryote is selected from ciliates, amoeba, protozoa, microsporea, myxosporia, platyhelminthes, nematods, and sporozoa.
13. The feed, feed supplement, or therapeutic composition of claim 1, wherein said animal is an aquatic animal.
14. The feed, feed supplement, or therapeutic composition of claim 13, wherein said aquatic animal is a crustacean.
15. The feed, feed supplement, or therapeutic composition of claim 14, wherein said crustacean is selected from shrimp, Artemia, lobster, crab, crayfish, prawn.
16. The feed, feed supplement, or therapeutic composition of claim 13, wherein said aquatic animal is a fish.
17. The feed, feed supplement, or therapeutic composition of claim 16, wherein said fish is selected from salmon, trout, halibut, turbot, striped bass, perch, tilapia, catfish, and carp.
18. The feed, feed supplement, or therapeutic composition of claim 1, wherein said animal is a terrestrial animal.
19. The feed, feed supplement, or therapeutic composition of claim 18, wherein said terrestrial animal is selected from horse, dog, cat, cow, sheep, goat, poultry, birds, mink, pig, hamster, mouse, rabbit, rat, gerbil, and guinea pig.
20. The feed, feed supplement, or therapeutic composition of claim 1, wherein said siRNA or dsRNA is expressed in organisms selected from insect, bacteria, fungi, bacteriophage, plants, and yeast.
21. The feed, feed supplement, or therapeutic composition of claim 20, wherein said organisms are included in the feed as whole or mostly whole cells.

22. The feed, feed supplement, or therapeutic composition of claim 20, wherein said organisms are included in the feed as broken or mostly broken cells.
23. The feed, feed supplement, or therapeutic composition of claim, 20, wherein the organism biomass is encapsulated.
24. The feed, feed supplement, or therapeutic composition of claim 23, wherein the encapsulation is accomplished using material selected from digestible polymer, non-digestible polymer, phospholipids, chitosan and alginate.
25. A method of protecting an animal from a pathogen comprising feeding said animal a feed, further comprising siRNA or dsRNA, wherein said siRNA or dsRNA being expressed in an organism, and said siRNA or dsRNA capable of being processed into siRNA and down regulating the expression of animal pathogen by RNA interference.
26. The method of Claim 25, wherein said pathogen is a virus, bacteria, or fungi.
27. The method of claim 26, wherein said virus is selected from White Spot Syndrome Virus, Taura Syndrome Virus, Yellow Head Virus, and Infectious Hypodermal and Hematopoietic Virus.
28. As in claim 26, wherein said virus is selected from porcine parvovirus (PPV), exotic necastle disease, foot and mouth disease (FMD), feline leukemia virus (FLV), canine parvovirus.
29. The feed, feed supplement, or therapeutic composition of claim 26, wherein said bacterium is selected from aquacultural or agricultural bacterial pathogens.
30. The feed, feed supplement, or therapeutic composition of claim 29, wherein said aquacultural bacterial pathogen is selected from *Aeromonas spp.*, *Edwardsiella spp.*, *Flavobacterium spp.*, *Flexibacter spp.*, *Mycobacterium sp.*, *Streptococcus spp.*, *Salmonella spp.*, *Vibrio spp.*, and *Yersinia reuckeri*.
31. The feed, feed supplement, or therapeutic composition of claim 29, wherein said agricultural bacterial pathogen is selected from *Mycobacterium spp.*, *Enterococcus spp.*, *Streptococcus spp.*, *Salmonella spp.*, and *Yersinia pestis*.
32. The feed, feed supplement, or therapeutic composition of claim 26, wherein said fungus is selected from aquacultural or agricultural fungal pathogens.

33. The feed, feed supplement, or therapeutic composition of claim 32, wherein said aquacultural fungal pathogen is selected from *Oomycetes fungi*, *Aphanomyces astaci*, and *Ichthyophonus spp.*
34. The feed, feed supplement, or therapeutic composition of claim 32, wherein said agricultural fungal pathogen is selected from *Trychophyton spp.*, *Fusarium solani*, and *Candida spp.*
35. The method of claim 25, wherein said pathogen is a eukaryote.
36. The method of claim 35, wherein said eukaryote is selected from ciliates, amoeba, protozoa, microsporea, myxosporia, platyhelminthes, nematods, and sporozoa.
37. The method of claim 25, wherein said animal is an aquatic animal.
38. The method of claim 37, wherein said aquatic animal is a crustacean.
39. The method of claim 38, wherein said crustacean is selected from shrimp, Artemia, lobster, crab, crayfish, prawn
40. The method of claim 37, wherein said aquatic animal is a fish.
41. The method of claim 40, wherein said fish is selected from salmon, trout, halibut, turbot, striped bass, perch, tilapia, catfish, and carp.
42. The feed, feed supplement, or therapeutic composition of claim 25, wherein said animal is a terrestrial animal.
43. The feed, feed supplement, or therapeutic composition of claim 42, wherein said terrestrial animal is selected from horse, dog, cat, cow, sheep, goat, poultry, birds, mink, pig, hamster, mouse, rabbit, rat, gerbil, and guinea pig.
44. The method of claim 25, wherein said siRNA or dsRNA is expressed in organisms selected from insect, bacteria, fungi, bacteriophage, plants, and yeast.
45. The method of claim 44, wherein said organisms are included in the feed as whole or mostly whole cells.
46. The method of claim 44, wherein said organisms are included in the feed as broken or mostly broken cells.
47. The method of claim 44, wherein the organism biomass is encapsulated.

48. The method of claim 47, wherein the encapsulation is accomplished using material selected from digestible polymer, non-digestible polymer, phospholipids, chitosan and algenate.
49. The method in Claim 25, wherein a feed that is supplemented with a recombinant bacterial cells containing 21 to 23 nucleotide long that selectively degrade the homologous mRNA with a disease-causing element to reduce or alleviate a disease state.

Ahne W, Bjorklund HV, Essbauer S, Fijan N, Kurath G, Winton JR (2002) Spring viremia of carp (SVC). *Dis Aquat Organ* 52:261-272

Altmann F, Staudacher E, Wilson IB, Marz L (1999) Insect cells as hosts for the expression of recombinant glycoproteins. *Glycoconj J* 16:109-123

Anderson MM, Lauring AS, Robertson S, Dirks C, Overbaugh J (2001) Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses. *J Virol* 75:10563-10572

Ausubel F et al. (1997) Short Protocols in Molecular Biology, 3 edn. John Wiley & Sons, Inc., New York

Bergeron J, Menezes J, Tijssen P (1993) Genomic organization and mapping of transcription and translation products of the NADL-2 strain of porcine parvovirus. *Virology* 197:86-98

Bootland L, Lizama M, Lin W, Saloni K (2002) Oral immunization of salmonids with biodegradable microparticle-based vaccines. In: Harrington K (ed) 4th Intl Symp Aquatic Animal Health, New Orleans, p 228

Buxton F, Gwynne D, Davies R (1990) *Aspergillus niger* transformation system US Patent 4885249 assigned to Allelix Inc. *Biotechnol Adv* 8:388-389

Byon JH, Lee JW, Lee DS, Nam TJ (2002) Low molecular weight polymannuronate. In: US Pat Publ 20020137723 A1

Castillo A, Cifuentes V (1994) Presence of double-stranded RNA and virus-like particles in *Phaffia rhodozyma*. *Curr Genet* 26:364-368

- Cereghino GP, Cregg JM (1999) Applications of yeast in biotechnology: protein production and genetic analysis. *Curr Opin Biotechnol* 10:422-427
- Cereghino JL, Cregg JM (2000) Heterologous protein expression in the methylotrophic yeast *Pichia pastoris*. *FEMS Microbiol Rev* 24:45-66
- Cha HJ, Dalal NG, Pham MQ, Vakharia VN, Rao G, Bentley WE (1999) Insect larval expression process is optimized by generating fusions with green fluorescent protein. *Biotechnol Bioeng* 65:316-324.
- Chang CF, Su MS, Chen HY, Liao IC (2003) Dietary beta-1,3-glucan effectively improves immunity and survival of *Penaeus monodon* challenged with white spot syndrome virus. *Fish Shellfish Immunol* 15:297-310
- Chen LL et al. (2002) Identification of a nucleocapsid protein (VP35) gene of shrimp white spot syndrome virus and characterization of the motif important for targeting VP35 to the nuclei of transfected insect cells. *Virology* 293:44-53
- Choi T-J, Kim Y-T, Kim D-H (2000) Biosynthesis of foreign proteins using transformed microalgae. In: World Intellectual Property Organization. ALGenetech
- Clark M (1997) Plant Molecular Biology. Springer, Berlin
- Cregg JM, Cereghino JL, Shi J, Higgins DR (2000) Recombinant protein expression in *Pichia pastoris*. *Mol Biotechnol* 16:23-52
- Dhar AK, Dettori T, Roux MM, Klipple K, Read B (2003) Identification of differentially expressed genes in white spot syndrome virus infected schrimp (*Penaeus stylirostris*) by cDNA microarrays. *Arch Virol* 148:2381-2396
- Dhar AK, Roux MM, Klimpel KR (2001) Detection and quantification of infectious hypodermal and hematopoietic necrosis virus and white spot virus in shrimp using real-time quantitative PCR and SYBR Green chemistry. *J Clin Microbiol* 39:2835-2845
- el-Enshasy H, Hellmuth K, Rinas U (2001) GpdA-promoter-controlled production of glucose oxidase by recombinant *Aspergillus niger* using nonglucose carbon sources. *Appl Biochem Biotechnol* 90:57-66

- Fischer R, Drossard J, Emans N, Commandeur U, Hellwig S (1999) Towards molecular farming in the future: pichia pastoris-based production of single-chain antibody fragments. Biotechnol Appl Biochem 30 (Pt 2):117-120
- Flegel T (1997) Major viral disease of black tiger prawn (*Penaeus monodon*) in Thailand. World J Micro Biotech 13:433-442
- Fuller JD et al. (2002) Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of *Streptococcus iniae* disease. Infect Immun 70:5730-5739
- Gibello A, Collins MD, Dominguez L, Fernandez-Garayzabal JF, Richardson PT (1999) Cloning and analysis of the L-lactate utilization genes from *Streptococcus iniae*. Appl Environ Microbiol 65:4346-4350
- Guthrie C, Fink G (1991) Guide to yeast genetics and molecular biology. In: Abelson J, Simon M (eds) Methods Enzymol. Academic Press, San Diego, CA
- Hannon GJ (2002) RNA interference. Nature 418:244-251
- Harel M (2003) Zooplankton enrichment with probiotics and prebiotics and uses thereof. In: PCT Publication WO03103692. Advanced BioNutrition Corp., USA
- Hoffman B, Schutze H, Mettenleiter TC (2002) Determination of the complete genomic sequence and analysis of the gene products of the virus of Spring Viremia of Carp, a fish rhabdovirus. Virus Res 84:89-100
- Huang LL, Larossa RA, McCluskey MP (2002) High level promoters from cyanobacteria. In: US Pat Publ 20020164706 A1
- Inouye K et al. (1994) Mass mortality of cultured kuruma shrimp *Penaeus japonicus* in Japan in 1993: Electron microscopic evidence of the causative virus. Fish Pathology 9:149-158
- Jarvis DL, Kawar ZS, Hollister JR (1998) Engineering N-glycosylation pathways in the baculovirus-insect cell system. Curr Opin Biotechnol 9:528-533
- Jory D, Dixon H (1999) Shrimp white spot virus in the Western Hemisphere. Aquacult Mag 25:83-91
- Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J (2002) Effectiveness of specific RNA-mediated interference through ingested double stranded RNA in *Caenorhabditis elegans*. Genome Biol 2:0002.0001-0002.0010

- Kamstrup S et al. (1998) Mapping the antigenic structure of porcine parvovirus at the level of peptides. *Virus Res* 53:163-173
- Kapusta J et al. (1999) A plant-derived edible vaccine against hepatitis B virus. *Faseb J* 13:1796-1799
- Kelemen Z et al. (2002) Transformation vector based on promoter and intron sequences of a replacement histone H3 gene. A tool for high, constitutive gene expression in plants. *Transgenic Res* 11:69-72
- Khandelwal A, Vally K, Geetha N, Venkatachalam P, Shaila M, Sita G (2003) Engineering hemagglutinin (H) protein of rinderpest virus into peanut (*Arachis hypogaea* L.) as a possible source of vaccine. *Plant Sci* 165:77-84
- Krishna R, Rao K, Rao PV, Babu P (1997) White spot disease. *World Aquaculture* 12:14-19
- Krossoy B et al. (2001) Cloning and identification of the infectious salmon anaemia virus haemagglutinin. *J Gen Virol* 82:1757-1765
- Lerrick JW, Yu L, Naftzger C, Jaiswal S, Wycoff K (2001) Production of secretory IgA antibodies in plants. *Biomol Eng* 18:87-94
- Lau S, Woo P, Tse H, Leung K, Wong S, Yuen K (2003) Invasive *Streptococcus iniae* Infections Outside North America. *J Clin Microbiol* 41:1004-1009
- Liu L, Liu J, Qiu RX, Zhu XG, Dong ZY, Tang GM (2003) Improving heterologous gene expression in *Aspergillus niger* by introducing multiple copies of protein-binding sequence containing CCAAT to the promoter. *Lett Appl Microbiol* 36:358-361
- Marks H, Mennens M, Vlak JM, van Hulten MC (2003) Transcriptional analysis of the white spot syndrome virus major virion protein genes. *J Gen Virol* 84:1517-1523
- Martinez C, Hermosilla G, Leon R, Pincheira G, Cifuentes V (1998) Genetic transformation of astaxanthin mutants of *Phaffia rhodozyma*. *Antonie Van Leeuwenhoek* 73:147-153.
- Mason HS, Lam DM, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. *Proc Natl Acad Sci U S A* 89:11745-11749
- Mayfield S, Franklin S, Lerner R (2003) Expression and assembly of a fully active antibody in algae. *Proc Nat Acad Sci USA*

- Mayfield S, Kindle K (1990) Stable nuclear transformation of *Chlamydomonas reinhardtii* by using a *C. reinhardtii* gene as the selectable marker. Proc Natl Acad Sci U S A 87:2087-2091
- McCown M, Diamond MS, Pekosz A (2003) The utility of siRNA transcripts produced by RNA polymerase I in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313:514-524
- Moll BA (1993) Methods and compositions for producing metabolic products for algae. In: US Patent 05270175. DNA Plant Technology Corporation
- Namikoshia A et al. (2004) Vaccination trials with *Penaeus japonicus* to induce resistance to white spot syndrome virus. Aquacult 229:25-35
- Neely MN, Pfeifer JD, Caparon M (2002) Streptococcus-zebrafish model of bacterial pathogenesis. Infect Immun 70:3904-3914
- Poulsen P (2002) Transgenic plants or algae expressing an AGP enzyme coupled to a transit peptide. In: US Patent 06379968. Danisco A/S
- Raponi M, Arndt GM (2003) Double-stranded RNA-mediated gene silencing in fission yeast. Nucleic Acids Res 31:4481-4489
- Reed AP, Jones EV, Miller TJ (1988) Nucleotide sequence and genome organization of canine parvovirus. J Virol 62:266-276
- Saliki JT et al. (1992) Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen Virol 73:369-374
- Saravanan T, Reddy GR, Dechamma HJ, Suryanarayana VV (2003) Foot-and-mouth disease virus Asia 1 (FMDV-Asia1). In. Molecular Virology, Indian Veterinary Research Institute, India
- Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM (1990) Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 64:3162-3170
- Sellers HS, Seal BS (2000) Complete sequence for the B1 strain of Newcastle disease virus. In. U.S. Department of Agriculture/Agriculture Research Services

- Shapira M, Arad SM, Lapidot M, Raveh D, Sivan A (2002) Stable chloroplast transformation of the unicellular red alga *Porphyridium* species. *Plant Physiol* 129:7-12
- Shoemaker CA, Klesius PH, Evans JJ (2001) Prevalence of *Streptococcus* in tilapia, hybrid striped bass, and channel catfish on commercial fish farms in the United States. *Am J Vet Res* 62:174-177
- Snow M, Ritchie R, Arnaud O, Villoing S, Aspehaug V, Cunningham CO (2003) Isolation and characterisation of segment 1 of the infectious salmon anaemia virus genome. *Virus Res* 92:99-105
- Sultana K, Godward G, Reynolds N, Arumugaswamy R, Peiris P, Kailasapathy K (2000) Encapsulation of probiotic bacteria with alginate-starch and evaluation of survival in simulated gastrointestinal conditions and in yoghurt. *Int J Food Microbiol* 62:47-55
- Taschner PE, van Marle G, Brederode FT, Tumer NE, Bol JF (1994) Plants transformed with a mutant alfalfa mosaic virus coat protein gene are resistant to the mutant but not to wild-type virus. *Virology* 203:269-276
- Ton G, Ni K, Cohen A, Mayfield S (2002) Construction of the anti-cocaine Fab genes for expression in the unicellular green alga *Chlamydomonas reinhardtii*. *FASEB J* 16:A542
- Toyomizu M, Suzuki K, Kawata Y, Kojima H, Akiba Y (2001) Effective transformation of the cyanobacterium *Spirulina platensis* using electroporation. *J Appl Phycol* 13:209-214
- Tsai MF et al. (2000a) Transcriptional analysis of the ribonucleotide reductase genes of shrimp white spot syndrome virus. *Virology* 277:92-99
- Tsai MF et al. (2000b) Identification and characterization of a shrimp white spot syndrome virus (WSSV) gene that encodes a novel chimeric polypeptide of cellular-type thymidine kinase and thymidylate kinase. *Virology* 277:100-110
- van Hulten MC, Goldbach RW, Vlak JM (2000a) Three functionally diverged major structural proteins of white spot syndrome virus evolved by gene duplication. *J Gen Virol* 81:2525-2529
- van Hulten MC, Westenberg M, Goodall SD, Vlak JM (2000b) Identification of two major virion protein genes of white spot syndrome virus of shrimp. *Virology* 266:227-236

van Hulten MC et al. (2001) The white spot syndrome virus DNA genome sequence. *Virology* 286:7-22

Vihinen-Ranta M, Wang D, Weichert WS, Parrish CR (2002) The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. *J Virol* 76:1884-1891

Villand P, Kleczkowski L, Olsen O-A, Poulsen P, Okkels F, Marcussen J (1999) Transgenic plants or algae expressing an AGP enzyme coupled to a transit peptide. In: US Patent 05977437. Danisco A/S

Vournakis J, Finkielstein S, Pariser E, Helton M (2001) Methods and compositions for poly-1-4-N-acetylglucosamine cell therapy system. In: US Pat Appl. 20010055807. Marine Polymer Technologies, USA

Walmsley AM, Arntzen CJ (2000) Plants for delivery of edible vaccines. *Curr Opin Biotechnol* 11:126-129

Weinstein MR et al. (1997) Invasive infections due to a fish pathogen, *Streptococcus iniae*. *S. iniae* Study Group. *N Engl J Med* 337:589-594

Wery J, Gutker D, Renniers AC, Verdoes JC, van Ooyen AJ (1997) High copy number integration into the ribosomal DNA of the yeast *Phaffia rhodozyma*. *Gene* 184:89-97.

Wiebe MG et al. (2001) Production of tissue plasminogen activator (t-PA) in *Aspergillus niger*. *Biotechnol Bioeng* 76:164-174

Wilson JA et al. (2003) RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. *Proc Natl Acad Sci U S A* 100:2783-2788

Xia H, Mao Q, Paulson HL, Davidson BL (2002) siRNA-mediated gene silencing in vitro and in vivo. *Nat Biotechnol* 20:1006-1010

Yang F et al. (2001) Complete genome sequence of the shrimp white spot bacilliform virus. *J Virol* 75:11811-11820

Yi G, Qian J, Wang Z, Qi Y (2003) A phage-displayed peptide can inhibit infection by white spot syndrome virus of shrimp. *J Gen Virol* 84:2545-2553

Zhang X, Xu X, Hew CL (2001) The structure and function of a gene encoding a basic peptide from prawn white spot syndrome virus. *Virus Res* 79:137-144

Zlotkin A, Hershko H, Eldar A (1998) Possible transmission of *Streptococcus iniae* from wild fish to cultured marine fish. *Appl Environ Microbiol* 64:4065-4067